RESUMO
Introducción. Mycoplasma genitalium (MG) es un reconocido patógeno de transmisión sexual. El aumento de las resistencias asociadas a las principales líneas de tratamiento (macrólidos y quinolonas) justifican un estudio genético de mutaciones para mejorar las tasas de curación. Material y métodos. Un total de 8.508 muestras fueron analizadas entre abril de 2018 y julio de 2022 para la detección de MG mediante la técnica de PCR multiplex AllplexTM STI Essential Assay. En los casos positivos para MG se estudió el dominio V del gen 23S rRNA y los genes gyrA y parC. Se evaluó la importancia clínica de las mutaciones y se revisaron las historias clínicas para obtener información demográfica y de tratamiento. Resultados. Se realizó estudio de resistencias a 92 muestras (65 hombres y 27 mujeres). En lo relativo al estudio genotípico, 28 pacientes presentaban mutaciones a macrólidos (30,43%). La más habitual fue A2059G (18.48%). Para las quinolonas, 5 pacientes (5,43%) presentaron mutaciones clínicamente relevantes en el gen parC. Destaca un paciente con la mutación G295 en gyrA asociada a G248T en parC. Treinta individuos se sometieron al test de cura (TOC). La azitromicina fue el régimen empírico más común y el moxifloxacino la principal alternativa. Conclusiones. La elevada tasa de resistencias en nuestro entorno evidencia la necesidad de realizar una terapia dirigida por el estudio genotípico de resistencias a macrólidos, apoyándonos en la detección de mutaciones en parC y gyrA para predecir la susceptibilidad a quinolonas y en el uso del TOC para evaluar la respuesta al tratamiento (AU)
Introduction. Mycoplasma genitalium (MG) is a recognized sexually transmitted pathogen. Increasing resistance to main lines of treatment (macrolides and quinolones) justifies a genetic study of mutations to improve cure rates. Material and methods. A total of 8,508 samples from April 2018 to July 2022 were processed using AllplexTM STI Essential Assay. In MG positive cases 23S rRNA V domain, gyrA and parC genes were studied. Mutations detected were checked to assess their clinical significance and medical records were reviewed to obtain demographic and treatment information. Results. Resistance study was performed on 92 samples (65 men and 27 women). In relation to the genotypic study, 28 patients presented mutations to macrolides (30.43%). Most common was A2059G (18.48%). For quinolones, 5 patients (5.43%) had clinically relevant mutations in parC gene. Of note was a patient with G295 mutation in gyrA associated with G248T in parC. Thirty subjects underwent a test of cure (TOC). Azithromycin was the most common empirical regimen and moxifloxacin the main alternative. Conclusions. High rate of resistance in our environment evidences the need for targeted therapy by genotypic study of macrolide resistance, supported by the detection of mutations in parC and gyrA to predict quinolones susceptibility and the use of TOC to evaluate treatment response (AU)
Assuntos
Humanos , Masculino , Feminino , Adolescente , Adulto Jovem , Adulto , Pessoa de Meia-Idade , Idoso , Antibacterianos/farmacologia , Farmacorresistência Bacteriana/genética , Fluoroquinolonas/farmacologia , Macrolídeos/farmacologia , Mycoplasma genitalium/efeitos dos fármacos , Infecções por Mycoplasma/microbiologia , Infecções por Mycoplasma/tratamento farmacológico , Antibacterianos/uso terapêutico , Fluoroquinolonas/uso terapêutico , Macrolídeos/uso terapêuticoRESUMO
No disponible
Assuntos
Humanos , Masculino , Adulto Jovem , Adulto , Pessoa de Meia-Idade , Chlamydia trachomatis/isolamento & purificação , Linfogranuloma Venéreo/diagnóstico , Coinfecção , Reação em Cadeia da Polimerase Multiplex , Reto/microbiologia , Minorias Sexuais e de GêneroRESUMO
No disponible
Assuntos
Humanos , Feminino , Gravidez , Ureaplasma/patogenicidade , Infecções por Ureaplasma/complicações , Trabalho de Parto Prematuro/etiologia , Corioamnionite/microbiologia , Complicações Infecciosas na Gravidez , Fatores de RiscoRESUMO
Recurrence of Clostridium difficile infection (CDI) has major consequences for both patients and the health system. The ability to predict which patients are at increased risk of recurrent CDI makes it possible to select candidates for treatment with new drugs and therapies (including fecal microbiota transplantation) that have proven to reduce the incidence of recurrence of CDI. Our objective was to develop a clinical prediction tool, the GEIH-CDI score, to determine the risk of recurrence of CDI. Predictors of recurrence of CDI were investigated using logistic regression in a prospective cohort of 274 patients diagnosed with CDI. The model was calibrated using the Hosmer-Lemeshow test. The tool comprises four factors: age (70-79 years and ≥80 years), history of CDI during the previous year, direct detection of toxin in stool, and persistence of diarrhea on the fifth day of treatment. The functioning of the GEIH-CDI score was validated in a prospective cohort of 183 patients. The area under the ROC curve was 0.72 (0.65-0.79). Application of the tool makes it possible to select patients at high risk (>50%) of recurrence and patients at low risk (<10%) of recurrence. GEIH-CDI score may be useful for clinicians treating patients with CDI.
Assuntos
Infecções por Clostridium/diagnóstico , Técnicas de Apoio para a Decisão , Recidiva , Idoso , Idoso de 80 Anos ou mais , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estudos ProspectivosRESUMO
No disponible
